SMS Lifesciences (SMSLIFE) | Financial Analysis & Statements
SMS Lifesciences India Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
825.0M
Gross Profit
308.6M
37.40%
Operating Income
78.9M
9.56%
Net Income
43.8M
5.31%
EPS (Diluted)
₹13.75
Balance Sheet Metrics
Total Assets
3.9B
Total Liabilities
1.8B
Shareholders Equity
2.1B
Debt to Equity
0.84
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
SMS Lifesciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.4B | 3.0B | 3.1B | 3.5B | 2.6B |
| Cost of Goods Sold | 2.2B | 2.1B | 2.3B | 2.6B | 1.9B |
| Gross Profit | 1.2B | 907.7M | 845.5M | 875.4M | 702.1M |
| Gross Margin % | 34.8% | 30.3% | 27.1% | 25.2% | 27.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 58.5M | 57.9M | 54.5M | 50.3M | 52.1M |
| Other Operating Expenses | 145.4M | 77.9M | 67.6M | 77.9M | 97.6M |
| Total Operating Expenses | 203.9M | 135.8M | 122.1M | 128.1M | 149.8M |
| Operating Income | 301.3M | 162.8M | 180.5M | 246.5M | 223.9M |
| Operating Margin % | 8.9% | 5.4% | 5.8% | 7.1% | 8.7% |
| Non-Operating Items | |||||
| Interest Income | 3.1M | 2.8M | 4.0M | 3.2M | 4.3M |
| Interest Expense | 84.6M | 99.5M | 64.2M | 57.0M | 41.6M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 261.9M | 98.5M | 165.9M | 327.3M | 195.7M |
| Income Tax | 74.6M | 35.2M | 52.2M | 74.3M | 60.1M |
| Effective Tax Rate % | 28.5% | 35.7% | 31.4% | 22.7% | 30.7% |
| Net Income | 187.3M | 63.3M | 113.8M | 253.0M | 135.6M |
| Net Margin % | 5.6% | 2.1% | 3.6% | 7.3% | 5.3% |
| Key Metrics | |||||
| EBITDA | 496.1M | 347.4M | 314.6M | 356.6M | 315.7M |
| EPS (Basic) | ₹66.51 | ₹30.08 | ₹37.92 | ₹83.76 | ₹44.84 |
| EPS (Diluted) | ₹66.51 | ₹30.08 | ₹37.92 | ₹83.76 | ₹44.84 |
| Basic Shares Outstanding | 3023287 | 3023287 | 3023287 | 3023287 | 3023287 |
| Diluted Shares Outstanding | 3023287 | 3023287 | 3023287 | 3023287 | 3023287 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
SMS Lifesciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.0M | 5.7M | 12.8M | 9.9M | 85.4M |
| Short-term Investments | 10.1M | 9.2M | 23.3M | 23.7M | 20.9M |
| Accounts Receivable | 687.9M | 513.5M | 460.6M | 338.3M | 341.5M |
| Inventory | 674.0M | 812.1M | 862.3M | 848.1M | 616.3M |
| Other Current Assets | 126.5M | 211.7M | 403.1M | -1.0K | 194.4M |
| Total Current Assets | 1.5B | 1.6B | 1.6B | 1.6B | 1.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 36.9M | 42.3M | 34.5M | 38.1M | 25.9M |
| Goodwill | 515.0K | 495.0K | 754.0K | 1.1M | 340.4M |
| Intangible Assets | 515.0K | 495.0K | 754.0K | 1.1M | 1.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 38.8M | 27.3M | -18.0K | 47.7M | -2.0K |
| Total Non-Current Assets | 2.4B | 2.4B | 2.4B | 2.0B | 1.8B |
| Total Assets | 3.9B | 3.9B | 3.9B | 3.6B | 3.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 532.7M | 591.3M | 596.7M | 778.9M | 611.4M |
| Short-term Debt | 664.0M | 651.8M | 442.4M | 374.1M | 255.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 77.7M | 98.6M | 40.0K | 56.5M | 167.5M |
| Total Current Liabilities | 1.4B | 1.4B | 1.3B | 1.4B | 1.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 200.1M | 355.4M | 562.5M | 421.9M | 391.4M |
| Deferred Tax Liabilities | 107.4M | 120.4M | 127.6M | 106.8M | 108.3M |
| Other Non-Current Liabilities | -1.0K | - | -1.0K | - | 60.0M |
| Total Non-Current Liabilities | 358.8M | 523.2M | 731.1M | 563.8M | 590.0M |
| Total Liabilities | 1.8B | 2.0B | 2.1B | 1.9B | 1.7B |
| Equity | |||||
| Common Stock | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M |
| Retained Earnings | 1.1B | 954.1M | 892.1M | 788.8M | 600.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.1B | 1.9B | 1.9B | 1.6B | 1.3B |
| Key Metrics | |||||
| Total Debt | 864.1M | 1.0B | 1.0B | 796.0M | 646.9M |
| Working Capital | 85.1M | 107.1M | 255.5M | 205.8M | 122.1M |
Balance Sheet Composition
SMS Lifesciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 261.9M | 98.5M | 142.4M | 200.4M | 195.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -13.8M | -35.2M | 72.5M | -554.3M | -68.5M |
| Operating Cash Flow | 289.7M | 124.7M | 251.1M | -320.5M | 151.3M |
| Investing Activities | |||||
| Capital Expenditures | -149.8M | -207.4M | -428.0M | -415.2M | -354.7M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | -1.2M | 0 | -20.2M |
| Investment Sales | 0 | 23.3M | 112.0M | 337.9M | 38.1M |
| Investing Cash Flow | -150.6M | -185.3M | -314.9M | -73.5M | -266.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -4.5M | -4.5M | -4.5M | - | - |
| Debt Issuance | 3.5M | 0 | 298.1M | 116.9M | 67.8M |
| Debt Repayment | -178.0M | -176.2M | -114.4M | -73.1M | -62.7M |
| Financing Cash Flow | -142.0M | -14.3M | 208.9M | 130.4M | -2.5M |
| Free Cash Flow | 187.1M | 34.4M | -338.6M | -623.9M | -3.9M |
| Net Change in Cash | -2.8M | -74.9M | 145.1M | -263.6M | -117.4M |
Cash Flow Trend
SMS Lifesciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
22.32
Price to Book
2.02
Price to Sales
1.24
PEG Ratio
0.73
Profitability Ratios
Profit Margin
5.54%
Operating Margin
11.90%
Return on Equity
8.99%
Return on Assets
4.83%
Financial Health
Current Ratio
1.06
Debt to Equity
31.37
Beta
0.31
Per Share Data
EPS (TTM)
₹61.83
Book Value per Share
₹682.92
Revenue per Share
₹1,116.58
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SMSLIFE | 3.6B | 22.32 | 2.02 | 8.99% | 5.54% | 31.37 |
| Biocon | 566.5B | 71.84 | 1.68 | 3.66% | 3.59% | 50.02 |
| OneSource Specialty | 202.8B | 936.63 | 3.11 | -0.31% | 1.42% | 21.93 |
| Zota Health Care | 39.4B | -62.53 | 12.61 | -24.83% | -15.37% | 56.90 |
| Dishman Carbogen | 26.5B | 22.30 | 0.42 | 0.06% | 4.25% | 40.20 |
| Panacea Biotec | 21.8B | 182.62 | 2.65 | -1.01% | -1.29% | 2.79 |
Financial data is updated regularly. All figures are in the company's reporting currency.





